Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec:101:247-248.
doi: 10.1016/j.ijid.2020.09.1454. Epub 2020 Oct 1.

Finding the right time for anti-inflammatory therapy in COVID-19

Giovanni de Simone  1 , Costantino Mancusi  2
Affiliations
Comment

Finding the right time for anti-inflammatory therapy in COVID-19

Giovanni de Simone et al. Int J Infect Dis. 2020 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The three stages of COVID-19, as proposed by Siddiqi and Mehra (Siddiqi and Mehra, 2020), with suggested pathophysiologically appropriate stage-related treatment. The larger the size of the characters within the figure, the stronger the recommendation. The duration of the stages is indicative and can vary substantially. The criteria suggested by Langer-Gould et al. (2020) might substantially help to determine the shift from stage I to stage II.
See this image and copyright information in PMC

Comment in

  • Editorial Response to Drs. Simone and Mancusi.
    Langer-Gould A. Langer-Gould A. Int J Infect Dis. 2020 Dec;101:367. doi: 10.1016/j.ijid.2020.09.1455. Epub 2020 Oct 2. Int J Infect Dis. 2020. PMID: 33017695 Free PMC article. No abstract available.

Comment on

References

    1. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. Online ahead of print. - DOI - PMC - PubMed
    1. IDSE Disappointing results from first phase 3 trial of tocilizumab for COVID-19. IDSE. 2020 https://www.idse.net/Covid-19/Article/07-20/Disappointing-Results-From-F... Online ahead of print.
    1. Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P., Veiga V.C., Avezum A. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2019014. Online ahead of print. - DOI - PMC - PubMed
    1. Cicchese J.M., Evans S., Hult C., Joslyn L.R., Wessler T., Millar J.A. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev. 2018;285(1):147–167. - PMC - PubMed
    1. de Simone G., Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134–135. - PMC - PubMed

Substances